ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Press Release
https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=g
FREMONT, CA, Dec. 07, 2023 (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company’s eight-week long ADHD Phase II part II clinical…
read more